What the FDA labels say about taking them together
Rosuvastatin and voclosporin
Voclosporin's FDA label of August 25, 2026 names rosuvastatin in its drug interactions section; the rosuvastatin labels PlainMeds reads (2) do not name voclosporin. The voclosporin label: “Monitor for adverse reactions such as myopathy and rhabdomyolysis when OATP1B1/OATP1B3 substrates are used concomitantly with LUPKYNIS and reduce the dosage of these substrates as recommended in their prescribing …”
Check it at the source: the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.); the voclosporin FDA label on DailyMed (effective August 25, 2026, Aurinia Pharma U.S., Inc.).
What does the rosuvastatin label say about voclosporin?
Rosuvastatin's label (effective September 4, 2026) and its 1 other brand-application label do not name voclosporin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed
What does the voclosporin label say about rosuvastatin?
Voclosporin label, drug interactionsMonitor for adverse reactions such as myopathy and rhabdomyolysis when OATP1B1/OATP1B3 substrates (e.g., simvastatin, atorvastatin, pravastatin, rosuvastatin, pitavastatin, fluvastatin) are used concomitantly with LUPKYNIS and reduce the dosage of these substrates as recommended in their prescribing information.
Source: FDA drug label (LUPKYNIS), Aurinia Pharma U.S., Inc., effective August 25, 2026 (SPL set 9f489295-1156-52c7-5fd0-5c4c52f9b813), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rosuvastatin | Voclosporin | |
|---|---|---|
| Labeled for | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0692 per tablet 40 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once